Efficacy Analysis of Gefitinib +/- Ficlatuzumab in Serum Proteomic Based Subgroups of Patients with Previously Untreated Lung Adenocarcinoma von Mok, T.S.K., Tan, E., Greater, S.L., Chang, G., Yang, J.C., Gyuris, J., Han, M., Komarnitsky, P., Payumo, F., Pestano, G., Roder, J., Spinella, D., Weng, Z., Park, K.

Volltext

205PEFFICACY ANALYSIS OF GEFITINIB +/- FICLATUZUMAB IN SERUM PROTEOMIC BASED SUBGROUPS OF PATIENTS WITH PREVIOUSLY UNTREATED LUNG ADENOCARCINOMA von Mok, T.S.K., Tan, E., Greater, S.L., Chang, G., Yang, J.C., Gyuris, J., Han, M., Komarnitsky, P., Payumo, F., Pestano, G., Roder, J., Spinella, D., Weng, Z., Park, K.

Volltext